{
    "xml": "<topic id=\"PHP410\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/nizatidine\" basename=\"nizatidine\" title=\"NIZATIDINE\">\n<title>NIZATIDINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_746\" namespace=\"/interactions/list-of-drug-interactions/ulcer-healing-drugs/histamine-h2-antagonists/nizatidine\">Nizatidine</xref>\n</p>\n<data name=\"vtmid\">108664005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_389169120\" title=\"H2-receptor antagonists\">H2-receptor antagonists</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34660\" title=\"H2-RECEPTOR ANTAGONISTS\" namespace=\"/drug-classes/h2-receptor-antagonists\">H2-RECEPTOR ANTAGONISTS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP70575\" outputclass=\"indicationsAndDose\" rev=\"1.24\" parent=\"/drugs/nizatidine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Benign gastric, duodenal or NSAID-associated ulceration</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>300&#8239;mg once daily for 4&#8211;8 weeks, dose to be taken in the evening, alternatively 150&#8239;mg twice daily for 4&#8211;8 weeks; maintenance 150&#8239;mg once daily, dose to be taken at night.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Gastro-oesophageal reflux disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8211;300&#8239;mg twice daily for up to 12 weeks.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70571\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/nizatidine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (histamine H<sub>2</sub>-antagonists).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70538\" outputclass=\"sideEffects\" rev=\"1.7\" parent=\"/drugs/nizatidine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Sweating</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Fever</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">vasculitis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70558\" outputclass=\"pregnancy\" parent=\"/drugs/nizatidine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70609\" outputclass=\"breastFeeding\" parent=\"/drugs/nizatidine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Amount too small to be harmful.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70583\" outputclass=\"hepaticImpairment\" parent=\"/drugs/nizatidine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70548\" outputclass=\"renalImpairment\" parent=\"/drugs/nizatidine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Use half normal dose if eGFR 20&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n<p>Use one-quarter normal dose if eGFR less than 20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70622\" outputclass=\"directionsForAdministration\" rev=\"1.12\" parent=\"/drugs/nizatidine\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Avoid rapid intravenous injection (risk of arrhythmias and postural hypotension).</p>\n<p>For intravenous infusion, give continuously or intermittently <i>in</i> Glucose 5% or Sodium chloride 0.9%. For continuous infusion, dilute 300&#8239;mg in 150&#8239;mL and give at a rate of 10&#8239;mg/hour; for intermittent infusion, dilute 100&#8239;mg in 50&#8239;L and give over 15 minutes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70494\" outputclass=\"exceptionsToLegalCategory\" rev=\"1.7\" parent=\"/drugs/nizatidine\">\n<title>Exceptions to legal category</title>\n<body>\n<section>\n<sectiondiv>\n<p>Nizatidine can be sold to the public for the prevention and treatment of symptoms of food-related heartburn and meal-induced indigestion in adults and children over 16 years; max. single dose 75&#8239;mg, max. daily dose 150&#8239;mg for max. 14 days.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP410-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/nizatidine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76999\" title=\"Capsule\" namespace=\"/drugs/nizatidine/capsule\">Capsule</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_746\" namespace=\"/interactions/list-of-drug-interactions/ulcer-healing-drugs/histamine-h2-antagonists/nizatidine\" title=\"Nizatidine\" count=\"1\" rel=\"link\">Nizatidine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34660\" namespace=\"/drug-classes/h2-receptor-antagonists\" title=\"H2-RECEPTOR ANTAGONISTS\" count=\"1\" rel=\"link\">H2-RECEPTOR ANTAGONISTS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76999\" namespace=\"/drugs/nizatidine/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n</links>\n</topic>",
    "id": "PHP410",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/nizatidine",
    "basename": "nizatidine",
    "title": "NIZATIDINE",
    "interactants": [
        {
            "id": "bnf_int_746",
            "label": "Nizatidine"
        }
    ],
    "vtmid": "108664005",
    "drugClassification": [
        "H2-receptor antagonists"
    ],
    "inheritsFromClass": [
        "H2-RECEPTOR ANTAGONISTS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Benign gastric, duodenal or NSAID-associated ulceration",
                        "html": "Benign gastric, duodenal or NSAID-associated ulceration"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "300 mg once daily for 4&#8211;8 weeks, dose to be taken in the evening, alternatively 150 mg twice daily for 4&#8211;8 weeks; maintenance 150 mg once daily, dose to be taken at night.",
                        "html": "<p>300&#8239;mg once daily for 4&#8211;8 weeks, dose to be taken in the evening, alternatively 150&#8239;mg twice daily for 4&#8211;8 weeks; maintenance 150&#8239;mg once daily, dose to be taken at night.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Gastro-oesophageal reflux disease",
                        "html": "Gastro-oesophageal reflux disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "150&#8211;300 mg twice daily for up to 12 weeks.",
                        "html": "<p>150&#8211;300&#8239;mg twice daily for up to 12 weeks.</p>"
                    }
                ]
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (histamine H2-antagonists).",
                "html": "<p>Appendix 1 (histamine H<sub>2</sub>-antagonists).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Sweating",
                        "html": "Sweating",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Fever",
                        "html": "Fever",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "vasculitis",
                        "html": "vasculitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless essential.",
                "html": "<p>Manufacturer advises avoid unless essential.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Amount too small to be harmful.",
                "html": "<p>Amount too small to be harmful.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution.",
                "html": "<p>Manufacturer advises caution.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Use half normal dose if eGFR 20&#8211;50 mL/minute/1.73 m2.\n\nUse one-quarter normal dose if eGFR less than 20 mL/minute/1.73 m2.",
                "html": "<p>Use half normal dose if eGFR 20&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>Use one-quarter normal dose if eGFR less than 20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Avoid rapid intravenous injection (risk of arrhythmias and postural hypotension).\n\nFor intravenous infusion, give continuously or intermittently in Glucose 5% or Sodium chloride 0.9%. For continuous infusion, dilute 300 mg in 150 mL and give at a rate of 10 mg/hour; for intermittent infusion, dilute 100 mg in 50 L and give over 15 minutes.",
                "html": "<p>Avoid rapid intravenous injection (risk of arrhythmias and postural hypotension).</p><p>For intravenous infusion, give continuously or intermittently <i>in</i> Glucose 5% or Sodium chloride 0.9%. For continuous infusion, dilute 300&#8239;mg in 150&#8239;mL and give at a rate of 10&#8239;mg/hour; for intermittent infusion, dilute 100&#8239;mg in 50&#8239;L and give over 15 minutes.</p>"
            }
        ]
    },
    "exceptionsToLegalCategory": {
        "exceptionsToLegalCategory": [
            {
                "type": "exceptionsToLegalCategory",
                "textContent": "Nizatidine can be sold to the public for the prevention and treatment of symptoms of food-related heartburn and meal-induced indigestion in adults and children over 16 years; max. single dose 75 mg, max. daily dose 150 mg for max. 14 days.",
                "html": "<p>Nizatidine can be sold to the public for the prevention and treatment of symptoms of food-related heartburn and meal-induced indigestion in adults and children over 16 years; max. single dose 75&#8239;mg, max. daily dose 150&#8239;mg for max. 14 days.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76999",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_746",
                "label": "Nizatidine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34660",
                "label": "H2-RECEPTOR ANTAGONISTS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76999",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    }
}